How Ovation Fertility and US Fertility LLC Exploit Vulnerable Families

1. Introduction

In a newly filed class action complaint, Ovation Fertility stands accused of misleading “hopeful parents” about the reliability and benefits of its Preimplantation Genetic Testing for Aneuploidy (PGT-A). According to the legal allegations, the most damning evidence revolves around how Ovation Fertility—or more formally, FPG Labs, LLC d/b/a Ovation Fertility, along with US Genetic Lab, LLC d/b/a Ovation Genetics—knowingly promoted genetic tests that, per the complaint, were never validated to the accuracy claims they advertised. The suit charges that these genetic tests, intended to screen human embryos for chromosomal abnormalities during In Vitro Fertilization (IVF), were touted as “greater than 98% accurate,” while studies cited in the complaint indicate that the real rate of accuracy may be far lower.

Furthermore, the lawsuit details how US Fertility LLC, having acquired Ovation Fertility in March 2023, allegedly exerts massive control over Ovation, effectively running it as an alter ego. Plaintiffs argue that the unproven reliability of Ovation’s PGT-A test misled IVF patients into discarding or overlooking potentially viable embryos. According to the complaint, these patients—already under physical, emotional, and financial strain—trusted Ovation’s claims that PGT-A reduces miscarriages, increases the chance of a healthy baby, and speeds the time to pregnancy. But the complaint alleges these bold marketing claims had no basis in independent, properly conducted clinical research.

By focusing on maximizing shareholder returns and fueling private equity investment, Ovation Fertility and US Fertility, per the suit, allegedly exposed families to staggering economic fallout. The complaint suggests that this pattern of corporate behavior epitomizes a broader environment of deregulation and regulatory capture under neoliberal capitalism, where, in the absence of robust oversight, corporate greed can overshadow corporate accountability. Ovation’s marketing, the plaintiffs say, left out material information: specifically, that many leading fertility experts, studies, and organizations (such as the American Society for Reproductive Medicine) do not endorse PGT-A as universally beneficial or proven to increase live birth rates.

In essence, the complaint reveals that IVF patients, some already grappling with repeated infertility challenges, spent thousands of dollars on Ovation’s add-on test without being adequately informed. As the allegations show, these decisions have ripple effects: from skyrocketing medical bills to profound stress over embryo viability and potential lost opportunities at parenthood. Local communities that revolve around fertility clinics—where individuals from all walks of life seek solutions—may be at the mercy of corporate behaviors that place profits over people. This article will systematically dissect the claims in the complaint and place them in the broader context of corporate corruption, wealth disparity, and the persistent ethical controversies that mark the intersection of for-profit health services and the vulnerability of patient populations.

---

2. Corporate Intent Exposed

The complaint, Klosowski, et al. v. FPG Labs, LLC, et al., lays out how Ovation Fertility promoted its PGT-A test to IVF patients nationwide. Plaintiffs cite specific marketing materials, including a uniform patient consent form, in which Ovation Fertility allegedly claimed:

1. PGT-A was more than 98% accurate.
2. PGT-A could reduce the risk of miscarriage.
3. PGT-A led to a faster time to pregnancy (labeled as “A Quicker Path to Pregnancy”).
4. PGT-A improved the chances of IVF success.
5. PGT-A effectively eliminated mosaic embryos (embryos with mixed chromosomal profiles).

Crucially, the complaint contends that Ovation never validated these success-rate claims, nor did it disclose findings from studies that question the reliability of trophectoderm biopsy—where only a small number of cells are sampled. The complaint further notes that embryos which test “aneuploid,” or “abnormal,” are often discarded, yet such classifications may be inaccurate. The fact that these alleged misrepresentations occur during one of the most stressful life events for many couples—amid repeated fertility treatments—makes the claims all the more incendiary.

Ovation’s Corporate Structure

The plaintiffs highlight that Ovation and its affiliate labs, collectively called Ovation Genetics, would conduct these tests and forward the results to patients. Although Ovation purportedly maintained the façade of a separate corporate identity, the complaint alleges that since the spring of 2023, US Fertility has consolidated the two into a single corporate behemoth. Plaintiffs go so far as to claim that the same small group of executives in US Fertility simultaneously run Ovation Fertility and direct its decision-making.

By controlling crucial aspects of Ovation’s marketing, operations, and profit distribution, US Fertility and its private equity backers allegedly turned PGT-A into a revenue source that soared from around 13% usage in IVF cycles to nearly 40%. This surge highlights the synergy between corporate consolidation and marketing expansions that prioritize profit margins. According to the complaint, these processes often leave patients—and even some reproductive specialists—under the impression that PGT-A is “proven” and “necessary,” when in fact, major professional societies have not endorsed its universal use.

Alleged Origins of Misrepresentation

Internal expansions, private equity acquisitions, and a drive for more billable procedures, as the complaint sets forth, created pressure to exaggerate PGT-A’s benefits. While Ovation’s website and consent forms openly tout success rates, the complaint states that relevant disclaimers (e.g., indicating PGT-A was experimental) are largely absent. Patients, therefore, see the test as an official, near-foolproof screening method:

“PGT-A is 98% accurate, allowing you to greatly reduce your risk of miscarriage.”
(Paraphrased from the complaint’s references to Ovation marketing materials.)

These claims, the lawsuit alleges, run contrary to longstanding, peer-reviewed studies cited in the complaint that question whether removing a few cells from a developing embryo can truly guarantee accurate detection of chromosomal abnormalities.

---

3. The Corporations Get Away With It

To understand how Ovation (and by extension, US Fertility) allegedly “gets away” with promoting an unvalidated test, the complaint delves into the structural weaknesses in the fertility industry’s oversight. Fertility clinics, labs, and allied genetic testing services often fall into a regulatory gap where the Food and Drug Administration (FDA) does not fully regulate certain laboratory-developed tests (LDTs). PGT-A, according to the complaint’s text, is one such LDT that never received explicit FDA approval or clearance.

Deregulation and Regulatory Capture

Although the complaint does not explicitly name “regulatory capture,” it points to a dynamic in which private equity–driven corporate entities operate with limited direct federal scrutiny. Insurance companies, as recounted in the complaint, consider PGT-A largely “unproven,” thus rarely covering it. This forces patients to pay out-of-pocket. However, the plaintiffs say such disclaimers from insurers did not stop Ovation from using marketing channels and sales teams to push the procedure.

Further, the complaint details how some large fertility practices—reportedly managed by US Fertility—funneled patients toward Ovation’s labs for PGT-A. This synergy exemplifies how corporate organizations can create vertical monopolies: from the fertility clinic (the pipeline) all the way to the testing lab. Under neoliberal capitalism, where markets reign supreme, these structures can exploit healthcare’s complexities without robust checks. Indeed, the suit underscores the lack of legal mandates requiring thorough, independent validation studies of PGT-A for the general fertility population.

Loopholes and Risk of Embryo Discard

The complaint raises the alarming prospect that a mislabeled “abnormal” embryo might be thrown away. These mistakes, if the allegations are accurate, can cost patients their one viable shot at pregnancy. This scenario resonates with a classic hazard of corporate pollution in a metaphorical sense: instead of polluting the environment, the system pollutes families’ hopes with inaccurate testing data. What makes it particularly galling is that few external gatekeepers—beyond the insurance companies that disclaim coverage—actively question such add-on tests.

By layering the testing claims with unverified assurances, the suit asserts, the company knowingly capitalized on patients’ vulnerability. The complaint identifies a standard “consent form” that repeated illusions of near-flawless accuracy with minimal disclaimers about potential false positives or mosaic results. Ovation allegedly omitted that major professional societies find “insufficient evidence” for PGT-A’s broad usage. In so doing, the complaint contends, Ovation reaped windfall profits from an unregulated testing environment with little immediate threat of enforcement or sanction.

---

4. The Cost of Doing Business

The complaint meticulously calculates how the cost of PGT-A—roughly $5,000 per IVF cycle, often out-of-pocket—can add steep financial burdens to individuals already paying tens of thousands for IVF itself. This outlay, as the suit posits, is a windfall for Ovation and US Fertility: a “revenue of hundreds of millions of dollars” from PGT-A across the fertility market. Unlike routine fertilization steps, the test is widely marketed as an “add-on” for couples who want “peace of mind.”

Private Equity’s Influence

Behind these sums stands private equity. According to the complaint, Morgan Stanley Capital Partners took a significant ownership stake in Ovation in 2019, only to sell it to US Fertility in 2023. Each transaction apparently signaled confidence in PGT-A’s profit potential. The alleged synergy is that US Fertility manages fertility practices—some with thousands of IVF cycles annually—and routes many to Ovation labs for PGT-A. In a highly profitable feedback loop, the more patients who buy PGT-A, the higher the labs’ margins and the more robust the shareholder returns.

Collateral Damage to Consumers

The complaint offers specific examples of how individuals paid for multiple PGT-A cycles, believing the test’s claims that it reduces miscarriages and speeds time to pregnancy. However, the complaint suggests these claims are baseless or heavily disputed. Thus, Plaintiffs argue they have been spending thousands of additional dollars (often financed or borrowed) for a test that “does not deliver on any scientifically validated improvement” in live birth rates.

This is a stark embodiment of how economic fallout occurs when corporations exploit the knowledge gap in medical decision-making. The alleged mismatch between marketing hype and clinical evidence means the “cost of doing business” is simply offloaded onto patients’ pockets.

Snowball Effect on IVF Timelines

Another dimension emerges in the complaint: questionable test results can require further rounds of egg retrieval, incurring more out-of-pocket costs, more hormone treatments, more sedation, and more emotional wear. Some patients allegedly ended up losing healthy embryos incorrectly tagged as “abnormal.” Others repeated the entire IVF cycle if they believed none of their biopsied embryos were viable. Meanwhile, Ovation and US Fertility, the suit says, collect their fees up front—leaving patients with the negative financial, physical, and emotional consequences.

---

5. Systemic Failures

Despite focusing on IVF patients specifically, the lawsuit illuminates how these controversies fit into a broader tapestry of systemic failures. As alleged, the test soared in adoption from around 13% of IVF cycles to 40% in the United States, without robust scientific consensus that it improves ultimate success. So how did we get here?

1. Limited Oversight of Laboratory-Developed Tests (LDTs): PGT-A falls into a niche where the complaint indicates there is no stringent FDA review. This scenario is reminiscent of other healthcare controversies where regulatory capture or inadequate frameworks let corporate labs flourish without firm accountability.
2. Deregulation in Healthcare Services: The complaint echoes a pattern across the US healthcare system: each “add-on” procedure, especially in fertility medicine, can be commercialized if it sounds attractive enough to prospective parents. With states having patchwork oversight for IVF, labs can tout “cutting-edge” technology while disclaiming official government endorsement.
3. Proprietary Testing Platforms: The complaint references how Ovation claims to employ advanced genetic sequencing methods but does not name any robust, peer-reviewed independent study that verifies its 98% accuracy. Without mandates for uniform external validation, test providers can pick data that suits them while ignoring broader contradictory evidence.
4. Information Asymmetry: Most intending parents have neither the time nor expertise to interpret conflicting scientific data. By controlling the narrative, the complaint argues, Ovation and US Fertility easily sidestep disclaimers about false positives or mosaicism. When patients assume these disclaimers must be minimal because the test is widely available, they fall deeper into the cycle of paying for unverified services.
5. Neoliberal Capitalism’s Profit Incentives: The complaint’s allegations exemplify how the drive for profit-maximization can overshadow corporate social responsibility. The complaint contends that Ovation’s push for expansions and acquisitions—fueled by investor capital—took priority over rigorous scientific demonstration of the test’s claims.

Together, these systemic lapses allowed Ovation to present PGT-A as a “game-changer” for IVF, the complaint says, perpetuating a cycle where the most vulnerable, hopeful consumers pay for a test whose utility remains questionable.

---

6. This Pattern of Predation Is a Feature, Not a Bug

A central theme arising from the complaint is that corporate corruption in the fertility space may not be an isolated aberration. Rather, it reflects a structural feature of late-stage capitalism, where the pursuit of shareholder value invites expansions into delicate territories such as embryo testing.

Pattern of Exploiting Vulnerability

The lawsuit underscores how IVF patients are uniquely vulnerable: Many have tried and failed to conceive naturally and pinned their hopes on medical interventions. The complaint contends that Ovation’s marketing exploited this emotional context, urging patients to go for an “add-on” test that would “ensure a healthier pregnancy.” This exploitative approach resonates with broader critiques of corporate greed, where capturing the “anxious consumer” is an intrinsic strategy rather than a bug in the system.

Wealth Disparity and IVF Access

By layering on a substantial cost to an already expensive procedure, the complaint argues that Ovation and US Fertility worsened wealth disparity in fertility treatments. Only affluent households or those with enough credit can afford repeated PGT-A cycles. Meanwhile, the less affluent either skip PGT-A (and thus forgo what the marketing portrays as a path to success) or go into debt. The entire system fosters a tiered approach to healthcare, seemingly contradictory to ethical “best practices” in medicine.

Amplification Through Deregulated Markets

The complaint’s allegations also highlight how markets—when left to their own devices—amplify unethical strategies in the name of growth. Because IVF labs are scattered across states with inconsistent regulations, a large entity like US Fertility can buy up labs or form alliances to funnel more and more patients into the same questionable test. In a sense, the profit-driven logic replicates itself, overshadowing the original medical mission of helping couples conceive. The complaint implies that, unless reined in, such expansions flourish.

Hence, the complaint posits that PGT-A’s climb to 40% usage is not a surprising glitch but an inevitable outcome of an environment where marketing spin can overshadow evidence-based medicine. “Predatory” is the word used to describe how Ovation collected fees from families, some of whom might have ended up discarding viable embryos or repeating entire IVF cycles, compounding the emotional turmoil and financial drain.

---

7. The PR Playbook of Damage Control

Although the complaint does not reference post-lawsuit corporate statements, it details the pattern in which Ovation Fertility and US Fertility advertised, marketed, and promoted PGT-A. The underlying structure of this marketing reveals a probable script for damage control that many corporations deploy when their practices face scrutiny:

1. Highlight “Advanced Technology”: Ovation’s promotional materials consistently tout the “most advanced technology available,” an almost reflexive claim to overshadow critics who question the test’s scientific basis. According to the complaint, their website and marketing brochures painted an image of cutting-edge genetics that no conscientious patient would want to “miss out on.”
2. Obfuscate or Downplay Limitations: The complaint states that disclaimers about false positives or potential embryo misclassification (e.g., mosaicism) were buried. Instead, bold claims about “A Quicker Path to Pregnancy” dominated. This strategic approach wards off uncomfortable questions.
3. Insist on High “Accuracy”: The repeated number—“98% accurate” or “99% accurate”—functions as a simple, compelling figure for promotional materials. Patients accept that number at face value. Meanwhile, critics or cautious experts might require robust peer-reviewed research, which, as alleged, Ovation lacks.
4. Emphasize Good Press Over Scientific Consensus: While the complaint does not mention actual press releases in detail, it does allege that Ovation routinely cited illusions of success rates without referencing independent scientific bodies or acknowledging that major professional associations found insufficient evidence to justify broad usage of PGT-A.
5. Tie in the Emotional Angle: IVF is inherently personal and emotional. By marketing PGT-A as the ultimate solution to heartbreak, the complaint indicates, Ovation seized on that vulnerability. Patients simply want the best chance at a healthy baby, so the PR narrative of “doing everything possible” overshadowed a deeper cost-benefit analysis.

Defensive Maneuvers

Even before the lawsuit, the complaint suggests Ovation’s marketing was structured to quell skepticism. Insurance companies calling PGT-A “experimental” might have triggered disclaimers, but these disclaimers were overshadowed by bold claims. As the complaint states, Ovation “omits material facts” or fails to mention professional guidelines. Such omissions often serve as a corporate strategy: if confronted, the company could deflect blame onto the consumer for not reading the fine print.

---

8. Profits Over People

According to the complaint’s allegations, the starkest measure of Ovation’s priorities is found in how the potential harm to human embryos and the emotional well-being of IVF patients took a back seat to sustaining private equity–fueled expansions. The complaint points out:

• Discarding Embryos Labeled “Aneuploid”: PGT-A results sometimes deemed an embryo “unsuitable for transfer.” If such labeling was inaccurate, a viable embryo could be lost forever. For many older patients or those with diminished ovarian reserve, that could be their only chance.
• Repeat Cycles, Repeat Revenue: If PGT-A results show no “normal” embryos, couples may pay for additional retrieval cycles (and more PGT-A tests). In short, the complaint suggests that each negative or ambiguous test “fuels the cycle anew,” generating additional fees for Ovation.
• Untested Efficacy: The complaint draws from external scientific consensus that there are no properly conducted, randomized, non-commercial trials supporting the broad claims of PGT-A. Nonetheless, these disclaimers seldom appeared in Ovation’s materials, and the lawsuit insists that the company not only knew of the controversies but chose to ignore them.

Maximizing Shareholder Returns in a Vulnerable Market

One chilling aspect is how the complaint frames Ovation’s profitability: the test is rarely covered by insurance, meaning patients are usually forced to pay out-of-pocket. The company thus taps directly into patient savings or credit, fueling an environment in which ironically the most desperate for success are the most profitable customers. That scenario encapsulates a classic moral hazard in neoliberal capitalism.

PGT-A becomes a perfect example of a service that is sold on the veneer of medical necessity but is not proven to yield better outcomes. By funneling marketing efforts toward intangible promises of “healthy pregnancies,” the complaint claims Ovation reaps easy revenue. The alleged corporate malfeasance underscores how such a dynamic weighs disproportionately on female patients, who endure the physical burdens of egg retrieval and IVF medication, and on couples who are willing to do almost anything to have a child.

---

9. The Human Toll on Workers and Communities

Although the complaint focuses primarily on consumer plaintiffs who underwent IVF with Ovation’s PGT-A, it also hints at a wider net of impact on local communities and clinic staff:

1. Emotional and Psychological Strain on IVF Patients: The complaint recounts how many individuals endure repeated hormone injections, sedation for egg retrievals, and the intense stress of waiting for embryo viability results. When PGT-A gives a false negative or positive, families can face the heartbreak of discarding an embryo or continuing to pay for more cycles. This mental toll fosters anxiety, depression, and heartbreak, further entrenching a sense of hopelessness or betrayal when they learn the test might be unproven.
2. Clinic Staff Pressures: While the complaint does not detail whistleblower affidavits, it does highlight that members of US Fertility (including various clinics) might be systematically trained to promote PGT-A. In a typical setting, embryologists and nurses face top-down directives to meet metrics for add-on services. Such an environment can turn well-intentioned professionals into unwitting participants in what plaintiffs label a “deceptive marketing strategy.”
3. Community Destabilization: Infertility rates have soared globally; individuals in local communities often rely on fertility clinics as they might rely on a hospital for critical care. If local practice owners succumb to acquisitions by big corporate networks (like US Fertility), those communities lose some measure of autonomy and oversight. Patients might see fewer second opinions or local labs. The complaint’s allegations about private equity infiltration can thus resonate beyond just the immediate plaintiffs, raising concerns of corporate ethics in healthcare access.
4. Public Health Implications: Although the complaint does not allege direct medical harm in terms of “public health crises,” the ripple effects of misrepresenting reproductive technologies can be severe: lost pregnancies, unnecessary surgeries, or the possibility that healthy embryos never see the light of day. This can be read as a “danger to the public health” on a psychological, emotional, and generational level.

These are, of course, allegations in a lawsuit. Nonetheless, the complaint’s descriptions of the emotional devastation from repeatedly unsuccessful cycles—possibly influenced by inaccurate PGT-A results—are vivid. They reveal an undercurrent: the commodification of reproductive medicine, where family-building is overshadowed by corporate interests.

---

10. Global Trends in Corporate Accountability

While the complaint zeroes in on Ovation’s PGT-A, it mirrors larger global trends. In many countries, government oversight bodies require that add-on reproductive treatments demonstrate robust, reproducible benefits. For instance, the suit references that certain insurance companies in the United States label PGT-A as “experimental” or “unproven.” Similarly, other nations with more centralized healthcare frameworks sometimes show more caution toward introducing new fertility “add-ons.”

However, lack of uniform regulation and the dominance of free-market ideologies in US healthcare have allowed corporations like Ovation to flourish with minimal accountability. In the complaint’s view, this is a direct reflection of how neoliberal capitalism encourages companies to treat scientific controversies as marketing opportunities. The complaint also suggests that transnational private equity might replicate the same patterns across global fertility markets if allowed.

Comparisons to Other Industries

In the broader world of corporate accountability, parallels can be drawn to how big pharmaceutical companies or medical device manufacturers sometimes proceed with under-validated products. Once corporate marketing claims become embedded, reversing them demands a daunting level of legal or regulatory confrontation. The complaint sets the stage for how, without robust third-party oversight:

• Companies can leverage widespread but flawed technology at scale.
• Consumer redress arrives late or not at all.
• Government or regulatory agencies may remain slow or unwilling to intervene, citing the complexities of “laboratory-developed tests.”

In short, absent legal pushback like the class action at issue, many of these allegations might remain “business as usual” in the for-profit reproductive medicine sector. The lawsuit’s purpose, from the plaintiffs’ vantage point, is to push the conversation from a simmering behind-the-scenes issue into a mainstream confrontation about corporate corruption and the ethical imperative to guard public health.

---

11. Pathways for Reform and Consumer Advocacy

The complaint seeks economic damages for the plaintiffs and the putative class, but it also calls for broad structural and declaratory relief. Although the legal text does not always detail the policy solutions, we can glean from the allegations certain recommendations to safeguard IVF patients and the public interest:

1. Stricter Regulatory Oversight: A consistent refrain is the urgent need for the FDA or comparable bodies to address the laboratory-developed test loophole. If PGT-A were subject to the same rigorous approval standards as, say, medical devices, the claims of “98% accuracy” would need robust backing.
2. Transparency in Marketing: The complaint points out that disclaimers and honest communication about the real limitations of PGT-A could help prospective parents make informed decisions. Mandating disclaimers about the test’s uncertain benefits and any contradictory guidelines from major fertility societies would be a start.
3. Independent Validation Studies: Plaintiffs highlight the near-total absence of large-scale, randomized, and unbiased clinical trials for PGT-A’s efficacy. One clear solution is requiring that such trials be completed (and results published) before labs can market the test widely. Corporate social responsibility demands that enterprises engaged in sensitive health services uphold validated science.
4. Consumer Advocacy and Class Actions: Class actions themselves are, as the complaint exemplifies, a tool for ensuring corporate accountability. Consumers who believe they have been misled can unite to demand compensation and systemic change. The lawsuit emphasizes that patients were “injured at the time of sale” and thus may claim restitution or disgorgement of ill-gotten profits.
5. Grassroots Initiatives and Whistleblower Protections: The fertility sector might see more employee whistleblowers if legal protections were strengthened. In such an environment, lab technicians or clinicians who see questionable scientific claims might step forward, providing impetus for early reform.

At its core, the complaint’s allegations revolve around a fundamental breach of trust. IVF patients risk everything—financially, physically, emotionally—to create life, only to find that corporate players allegedly placed profits over people. The clarion call from these allegations is loud: unless reined in by robust oversight, corporate expansions in the fertility industry can lead to wealth disparity, heartbreak for families, and systemic harm that cannot easily be undone. The precarious nature of embryo viability makes the cost of misguided policies uniquely devastating.

While corporations race to capture new reproductive markets, real human lives and potential futures hang in the balance.

---

💡 Explore Corporate Misconduct by Category

Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.

• 💀 Product Safety Violations — When companies risk lives for profit.
• 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
• 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
• 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
• 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.